CN114137214A - Immunoassay kit for predicting psychological symptoms after stress and application - Google Patents
Immunoassay kit for predicting psychological symptoms after stress and application Download PDFInfo
- Publication number
- CN114137214A CN114137214A CN202111475342.5A CN202111475342A CN114137214A CN 114137214 A CN114137214 A CN 114137214A CN 202111475342 A CN202111475342 A CN 202111475342A CN 114137214 A CN114137214 A CN 114137214A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- depression
- anxiety
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 75
- 238000003018 immunoassay Methods 0.000 title claims abstract description 19
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 70
- 239000000090 biomarker Substances 0.000 claims abstract description 63
- 230000036506 anxiety Effects 0.000 claims abstract description 58
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 51
- 102000004207 Neuropilin-1 Human genes 0.000 claims abstract description 38
- 108090000772 Neuropilin-1 Proteins 0.000 claims abstract description 38
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims abstract description 29
- 102100032404 Cholinesterase Human genes 0.000 claims abstract description 29
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims abstract description 29
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims abstract description 29
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 claims abstract description 16
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 claims abstract description 16
- 102000016938 Catalase Human genes 0.000 claims abstract description 15
- 108010053835 Catalase Proteins 0.000 claims abstract description 15
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 13
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 42
- 102000004169 proteins and genes Human genes 0.000 abstract description 42
- 210000004369 blood Anatomy 0.000 abstract description 36
- 239000008280 blood Substances 0.000 abstract description 36
- 230000003304 psychophysiological effect Effects 0.000 abstract description 9
- 239000000427 antigen Substances 0.000 abstract description 2
- 102000036639 antigens Human genes 0.000 abstract description 2
- 108091007433 antigens Proteins 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 36
- 208000020401 Depressive disease Diseases 0.000 description 33
- 208000014674 injury Diseases 0.000 description 17
- 230000008733 trauma Effects 0.000 description 17
- 206010054089 Depressive symptom Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 description 13
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 description 13
- 206010052428 Wound Diseases 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 208000020016 psychiatric disease Diseases 0.000 description 12
- 230000000472 traumatic effect Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- -1 CAT) Proteins 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 235000019624 protein content Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 4
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 4
- 102100028762 Neuropilin-1 Human genes 0.000 description 4
- 102000058223 human VEGFA Human genes 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 102000014105 Semaphorin Human genes 0.000 description 2
- 108050003978 Semaphorin Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000010833 quantitative mass spectrometry Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102100026063 Exosome complex component MTR3 Human genes 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 102100030892 Fructose-1,6-bisphosphatase isozyme 2 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000930766 Homo sapiens Far upstream element-binding protein 2 Proteins 0.000 description 1
- 101001063910 Homo sapiens Fructose-1,6-bisphosphatase isozyme 2 Proteins 0.000 description 1
- 101000974015 Homo sapiens Nucleosome assembly protein 1-like 1 Proteins 0.000 description 1
- 101000992283 Homo sapiens Optineurin Proteins 0.000 description 1
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 102000002111 Neuropilin Human genes 0.000 description 1
- 108050009450 Neuropilin Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000001366 chromaffin granule Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005300 mitochondrial iron ion transport Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a biomarker for predicting psychosocial symptoms such as anxiety and depression after stress and a detection kit thereof. The invention provides a group of biomarkers capable of predicting the occurrence of psychophysiological symptoms such as anxiety and depression after stress in the blood of potential patients, wherein the biomarkers are selected from one or more of butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2, neuropilin1 or amino acid sequences with 80% homology with the butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2 and neuropilin 1. The invention also provides a detection kit and a detection method for detecting the proteins in the blood sample; and the use of the above antigen and kit; and a reference concentration threshold value providing a high risk of anxiety and depression after stress of the proteins. The immunoassay kit prepared from the protein can quickly, simply and accurately detect the concentration of the biomarker in blood, and is suitable for large-scale popularization and application.
Description
Technical Field
The present invention relates to the detection and identification of biomarkers produced in subjects suffering from psychophysiological symptoms such as anxiety and depression after stress and provides a metric for predicting high risk of developing in subjects potentially suffering from anxiety and depression. In particular to a group of biomarkers for predicting the occurrence of psychological symptoms such as anxiety and depression after stress, a detection kit and a detection method for detecting the biomarkers in a blood sample, and provides a reference concentration threshold value of the markers with high occurrence risk, so that the reliable detection and identification of the biomarkers for assisting the diagnosis and prevention of the psychological symptoms such as anxiety and depression after stress are possible.
Background
In recent years, the incidence rate of stressful events such as public health emergencies, various major accidents, natural and artificial disasters gradually increases, more than 70% of people worldwide experience at least one traumatic event in a lifetime, and psychological symptoms such as anxiety and depression often appear after the stressful event for rescuers such as event experience persons and medical staff involved in rescue, and some individuals even develop serious mental diseases. Among them, post-traumatic stress disorder (PTSD) is one of the more serious mental diseases. Post-traumatic stress disorder refers to a mental disorder that is delayed in the appearance and persistence of an individual after the individual experiences, witnesses, or encounters one or more physical deaths involving themselves or others, or is threatened by death, or is severely injured, or is threatened by physical integrity. Clinically manifested as invasion of wound memory, avoidance of wound-related stimuli, negative changes in cognition, increased arousal and behavioral hyperactivity. According to the cultural background and the economic development level of different national regions, the lifetime prevalence rate of PTSD is about 1.3% -12.2%, and the annual prevalence rate is about 0.2% -3.8%. In today's society, post-stress mental illness, including PTSD, has become a disease of great concern, especially during the current COVID-19 pandemic. The disease has a long course and is easy to relapse, the patient often has behaviors of self-disability, suicide, drug abuse and the like, the life quality of the patient is seriously influenced, and the serious psychological, physiological and economic burden is caused to the individual, the family and the society.
PTSD is the most serious and most interesting disease in the post-stress psychiatric category, and the clinical diagnostic criteria of which are currently widely accepted are DSM-5 of the American society for mental medicine and ICD-11 of the world health organization. In DSM-5, the diagnostic criteria for PTSD have 8 large entries, divided into 4 symptom clusters and a subtype, where the 4 large symptom clusters are invasive in wound memory, avoidance of wound-related stimuli, negative changes in cognition and mood, increased arousal and behavioral hyperactivity. Whereas in ICD-11, the diagnosis of PTSD is simplified to 3 symptom groups for 6 categories of symptoms, including constant reexperiencing to traumatic events, avoidance of traumatic stimuli, and a high degree of vigilance. Although the diagnostic criteria for PTSD are slightly different, the treatment modalities include mainly psychological interventions, drug therapies and some other innovative therapies. Psychological intervention is recommended as the first-line treatment in most guidelines, and mainly includes prolonged exposure therapy, cognitive processing therapy, cognitive behavioral therapy, ocular desensitization, and reprocessing therapy. While drug therapy is generally used as a second line therapy, including selective 5-hydroxytryptamine reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidases, sympatholytic agents, anticonvulsants, benzodiazepines, and the like.
Although the incidence of PTSD is high in people who experience one or more severe wounds, not all individuals who experience a wound become PTSD patients, and the actual lifetime prevalence of PTSD is far below the theoretical presumptive value, suggesting that there is significant individual variability in the incidence of PTSD. PTSD incidence rate research based on different ethnic groups discovers that the incidence rate of white race is obviously lower than that of other races, and the twin-based research also discovers that the incidence rate of homozygotic twins is obviously higher than that of heterozygotic twins after suffering from traumatic events, and suggests that genetic factors obviously influence the incidence rate of PTSD. At present, PTSD is mainly diagnosed based on the medical history of a patient, mental state judgment, symptom duration, clinical mental scale detection and self-description of the patient, and the detection of objective and effective biomarkers of PTSD is lacked. Predicting risk factors for the occurrence of PTSD after a trauma event becomes particularly important given that the occurrence of most traumatic events is unavoidable. However, PTSD is less subject to screening and research on objective, effective and specific biological markers, and currently, there is still no objective index for PTSD early warning diagnosis and therapeutic efficacy evaluation. The detection of biomarkers in blood is considered to be the most potential and convenient way to facilitate PTSD diagnosis due to its advantages of convenience, minimal invasiveness, and the like. Studies have reported that a decrease in cortisol levels in blood following trauma may be associated with the development of PTSD, and imbalance in partial neurotransmitters in blood, levels of adrenocorticotropic hormone (ACTH), Glucocorticoid (GC), epinephrine, and catecholamine, and the like are also considered as markers associated with PTSD. In addition, other biomarkers that may be associated with PTSD include cholecystokinin (CCK), Nitric Oxide Synthase (NOS), neuropeptide y (npy), and p11 protein, among others. However, the specificity and sensitivity of these markers have not been well validated. Meanwhile, specific markers of mental diseases after stress other than PTSD are more rarely reported, and therefore, it is urgently required to discover and develop and utilize specific biomarkers for mental symptoms such as anxiety and depression after stress.
Therefore, in order to effectively predict the occurrence of psychophysiological symptoms such as anxiety and depression after stress, it is necessary to identify completely novel biomarkers and develop a detection kit capable of specifically detecting the biomarkers.
Disclosure of Invention
In order to solve the above problems, the present invention provides a set of biomarkers for predicting the occurrence of psychological symptoms such as anxiety and depression after stress, and a detection kit and a detection method for detecting the biomarkers in a blood sample, wherein the detection kit based on the biomarkers can be used for detecting the concentration of the biomarkers in the blood of a potential stress patient with high sensitivity, high specificity and high stability, and according to the concentration threshold provided by the invention, the high occurrence risk of the psychological symptoms such as anxiety and depression is prompted, so that the basis can be provided for doctors to accurately predict the occurrence of mental diseases such as anxiety, depression and PTSD of the stress patient, and further to take treatment in time to prevent the occurrence of the diseases and relieve the pain and burden of the patient in time, and the immunoassay kit prepared by the biomarkers can quickly, simply and accurately detect the concentration of the biomarkers in the blood, is suitable for large-scale popularization and application.
In order to achieve the above objects, according to a first aspect of the present invention, there is provided an immunoassay kit for predicting the occurrence of psychophysiological symptoms such as anxiety and depression after stress, the immunoassay kit comprising a reagent for quantitatively detecting the expression level of a biomarker selected from the group consisting of: butyrylcholinesterase (BCHE), Catalase (CATase, CAT), Dopamine-Beta-Hydroxylase (DBH), Insulin-Like Growth Factor Binding Protein 2(Insulin Like Growth Factor Binding Protein 2, IGFBP2), Neuropilin 1(Neuropilin1, NRP1), an amino acid sequence having at least 80% homology with the amino acid sequence of BCHE, an amino acid sequence having at least 80% homology with the amino acid sequence of CAT, an amino acid sequence having at least 80% homology with the amino acid sequence of DBH, an amino acid sequence having at least 80% homology with the amino acid sequence of IGFBP2, and an amino acid sequence having at least 80% homology with the amino acid sequence of NRP 1.
Preferably, the psychosocial symptoms such as anxiety and depression after stress include anxiety after stress, depression after stress, post traumatic stress disorder, anxiety after stroke, depression after stroke, anxiety after brain trauma, depression after brain trauma and other stress-related mental diseases.
In a second aspect of the present invention, there is provided a use of a biomarker for preparing an agent for quantitatively measuring the expression level of the biomarker for predicting the occurrence of psychophysiological symptoms after stress, the biomarker being selected from the group consisting of: butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2, neuropilin1, an amino acid sequence having at least 80% homology with the amino acid sequence of butyrylcholinesterase, an amino acid sequence having at least 80% homology with the amino acid sequence of catalase, an amino acid sequence having at least 80% homology with the amino acid sequence of dopamine-beta-hydroxylase, an amino acid sequence having at least 80% homology with the amino acid sequence of insulin-like growth factor binding protein 2, and an amino acid sequence having at least 80% homology with the amino acid sequence of neuropilin 1.
In a third aspect of the invention, there is provided a method of immunoassay kit for detecting the level of the above biomarker protein in whole blood, central nervous system tissue, serum, plasma, cerebrospinal fluid, saliva, sweat, tears, urine, oral sample, or a combination thereof. Preferably, the body fluid is blood. The method for detecting the above-mentioned protein can be carried out by a conventional Enzyme-linked immunosorbent assay (ELISA), preferably by using a sandwich ELISA method.
Preferably, the immunoassay kit further comprises a carrier, and the antigen for detecting the biomarker protein is coated on the carrier.
Preferably, the immunoassay kit further comprises a primary antibody, wherein the primary antibody is used for detecting the biomarker protein.
Preferably, the immunoassay kit further comprises a labeled secondary antibody of the biomarker protein primary antibody. The label can be horseradish peroxidase, alkaline phosphatase, fluorescent molecule FITC (or other fluorescent labels), and chemiluminescence detection. The detection method can be qualitative and quantitative analysis by a color development method, a fluorescence method, chemiluminescence and an electrochemiluminescence method.
More preferably, the labeled secondary antibody against the primary antibody against the biomarker protein is a secondary antibody against the primary antibody against the protein labeled by horseradish peroxidase.
In a fourth aspect of the invention, there is provided the use of an immunoassay kit for the above biomarker protein in the detection of the above biomarker protein in human blood to determine a high risk concentration threshold for the above protein by comparing the measured level of the above biomarker protein in a subject (e.g., a patient who has experienced a traumatic event) with the measured level of the above biomarker protein by quantitative mass spectrometry techniques.
The invention has the beneficial effects that: the biomarker capable of predicting the occurrence of psychological symptoms such as anxiety and depression after stress is one or more of Butyrylcholinesterase (BCHE), Catalase (Catalase, CAT), Dopamine-Beta-Hydroxylase (DBH), Insulin-Like Growth Factor Binding Protein 2 (IGFBP 2), Neuropilin 1(Neuropilin1, NRP1), an amino acid sequence having at least 80% homology with the amino acid sequence of BCHE, an amino acid sequence having at least 80% homology with the amino acid sequence of CAT, an amino acid sequence having at least 80% homology with the amino acid sequence of DBH, an amino acid sequence having at least 80% homology with the amino acid sequence of FBP2, and an amino acid sequence having at least 80% homology with the amino acid sequence of NRP1, and potential patients after stress events, the concentration of the biomarker protein can be detected in blood with high specificity, high sensitivity and high specificity, so that the method can provide a basis for doctors to accurately predict stress patients suffering from anxiety, depression, PTSD and other mental diseases, and then timely take treatment to prevent the occurrence of the diseases and timely relieve the pain and burden of the patients.
Drawings
FIG. 1 is a graph comparing the protein levels of BCHE in serum of patients with post-traumatic anxious depressive symptoms and patients with post-traumatic anxious depressive symptoms.
FIG. 2 is a graph showing the comparison of the protein level of CAT in serum of a patient having no anxiety and depression symptoms after trauma and a patient having anxiety and depression symptoms after trauma.
FIG. 3 is a graph showing a comparison of the protein level of DBH in serum of a patient having no anxiety-depressive symptom after trauma and a patient having anxiety-depressive symptom after trauma.
FIG. 4 is a graph comparing the protein levels of IGFBP2 in the serum of patients with post-traumatic anxiety-free depressive symptoms and patients with post-traumatic anxiety-depressive symptoms.
FIG. 5 is a graph comparing the protein level of NRP1 in serum of patients with post-traumatic anxiety-free depressive symptoms and patients with post-traumatic anxiety-depressed symptoms.
Detailed Description
In order to clearly understand the technical contents of the present invention, the following examples are given in detail.
Protein biomarkers
Biomarkers for predicting the occurrence of psychophysiological symptoms such as anxiety and depression after stress are Butyrylcholinesterase (BCHE), Catalase (Catalase, CAT), Dopamine-Beta-Hydroxylase (DBH), Insulin-Like Growth Factor Binding Protein 2 (IGFBP 2), Neuropilin 1(Neuropilin1, NRP 1).
BCHE is an esterase with broad substrate specificity that contributes to the inactivation of the neurotransmitter acetylcholine. BCHE degrades neurotoxic organophosphates. As shown in figure 1, the present invention identifies that levels of BCHE protein in whole blood, plasma, serum of patients experiencing symptoms of anxiety depression after trauma are significantly reduced (p <0.05) compared to levels in patients experiencing symptoms of anxiety depression after trauma.
CAT is present in almost all organisms that breathe aerobically and serves to protect cells from the toxic effects of hydrogen peroxide. CAT promotes cell growth, including T cells, B cells, myeloid leukemia cells, melanoma cells, mast cell tumor cells, and normal and transformed fibroblasts. As shown in figure 2, the present invention identifies that CAT protein levels in whole blood, plasma, serum of patients experiencing symptoms of anxiety depression after trauma are significantly reduced (p <0.05) compared to levels in patients experiencing symptoms of anxiety depression after trauma.
DBH protein is expressed in neurosecretory vesicles and chromaffin granules of the adrenal medulla, catalyzing the conversion of dopamine to norepinephrine, which is both a hormone and the major neurotransmitter of the sympathetic nervous system. DBH exists in soluble and membrane bound forms, depending on the absence or presence of the signal peptide, respectively. This gene mutation results in dopamine- β -hydroxy acid deficiency in human patients characterized by defects in autonomic and cardiovascular function, including hypotension and ptosis. The present invention identifies that the levels of DBH protein in whole blood, plasma, serum of patients experiencing symptoms of anxiety depression after trauma are significantly reduced (p <0.05) compared to the levels in patients experiencing symptoms of anxiety depression after trauma.
IGFBP2 inhibits IGF-mediated growth and development rates. IGFBP2 extends the half-life of IGFs and has been shown to inhibit or stimulate the growth promoting effects of IGFs on cell culture. IGFBP2 alters IGF interaction with its cell surface receptors. The present invention identifies that IGFBP2 protein levels in whole blood, plasma, serum of patients experiencing symptoms of anxiety depression after trauma are significantly reduced (p <0.05) compared to levels in patients experiencing symptoms of anxiety depression after trauma.
NRP1 is a cell surface receptor involved in the development of the cardiovascular system, angiogenesis, formation of neural circuits, and organogenesis outside the nervous system. NRP1 mediates the chemorepulsive activity of semaphorin. NRP1 recognizes the motif R/KXXR/K on its ligand as a rule of C-terminus, leading to cellular internalization and vascular leakage. It binds to semaphorin 3A, the PLGF-2 subtype of PGF, the VEGF165 subtypes VEGFA and VEGFB. The co-expression of NRP1 with KDR results in increased binding of VEGF165 to KDR and increased chemotaxis. NRP1 modulates VEGF-induced angiogenesis. NRP1 in combination with VEGFA initiated the signaling pathway required for motor neuron axon guidance and cell body migration, including facial motor neuron migration (by similarity) from diamond 4 to the caudal side of diamond 6 during embryonic development. NRP1 regulates mitochondrial iron transport by interacting with ABCB 8/mitosus. NRP1 binds VEGF-165 and may inhibit its binding to cells. NRP1 can induce apoptosis by sequestering VEGF-165. NRP1 may also bind to various members of the semaphorin family. NRP1 expression has a negative impact on blood vessel number and integrity. NRP1 acts as a host factor for infection by human coronavirus SARS-CoV-2. NRP1 recognizes and binds with C-terminal rules to the motif RRAR on SARS-CoV-2 spinous process protein S1 to enhance infection with SARS-CoV-2. The present invention identifies that NRP1 protein levels in whole blood, plasma, serum of patients experiencing symptoms of anxiety depression after trauma are significantly reduced (p <0.05) compared to levels in patients experiencing symptoms of anxiety depression after trauma.
Reagent kit
In the invention, five enzyme-linked immunoassay kits are used for detecting 5 serum biomarkers (BCHE, CAT, DBH, IGFBP2, NRP1) of psychopsychological symptoms such as anxiety and depression after stress. The assay is performed by a sandwich ELISA method.
1. Establishment of Sandwich ELISA method
1) According to the number of the detection samples, a plurality of costar bars are measured, wherein the costar bars are coated with the biomarker for resisting psychopsychological symptoms such as anxiety and depression after stress.
2) 100ul of sample diluent was added per well.
3) The standard, blank and diluted serum samples were added at 50 ul/well for 2 hours at 37 degrees, and shaker 200 rpm.
4) PBST wash, 400 ul/well, 5 times, pat dry.
5) Add another horseradish peroxidase labeled biomarker primary antibody, 200 ul/well, incubate at 37 ℃ for 2 hours, shaker 200 rpm.
6) PBST wash, 400 ul/well, 5 times, pat dry.
7) TMB color development, wherein TMB solution A and B solution are mixed in equal volume, 100 ul/hole, and 37 ℃ for 20 min.
8) Stop solution, 50 ul/well stop, read 450nm with microplate reader.
2. The kit comprises the following components:
the kit consists of the following parts:
1) coating costar enzyme plates for detecting biomarker-antibody for resisting psychology symptoms such as anxiety and depression after stress
2) One tube (1ml) of PTSD biomarker standard sample each
3) Sample diluent a bottle (100ml)
4) Tubes of horseradish peroxidase-labeled anti-biomarker antibody (20ml)
5) 10 PBST one bottle (100ml)
6) One bottle (60ml) of TMB color developing solution A and one bottle (60ml) of B solution B
7) One bottle of stop solution (60ml)
3. Identification of biomarkers for psychosocial symptoms such as anxiety and depression after stress
1) And the patient: 11 outpatients who underwent brain trauma were evaluated 6 months after brain trauma for the presence of anxious depressive symptoms by 2 psychiatrists according to the diagnostic criteria of DSM-5, 8 of which were not anxious depressive symptoms and were not diagnosed as PTSD and 3 of which were anxious depressive symptoms and were diagnosed as PTSD. The demographic data for 11 patients are shown in table one:
table one: demographic data of 11 outpatient brain trauma patients
| Brain trauma patient numbering | Sex | Age (age) | Diagnosis of |
| PT-071 | Female with a view to preventing the formation of wrinkles | 25 | Anxious depression, non-PTSD |
| PT-072 | Female with a view to preventing the formation of wrinkles | 34 | Anxious depression, non-PTSD |
| PT-073 | Female with a view to preventing the formation of wrinkles | 30 | Anxious depression, non-PTSD |
| PT-076 | Female with a view to preventing the formation of wrinkles | 24 | Anxious depression, non-PTSD |
| PT-078 | Female with a view to preventing the formation of wrinkles | 44 | Anxious depression, non-PTSD |
| PT-079 | Male sex | 55 | Anxious depression, non-PTSD |
| PT-083 | Male sex | 29 | Anxious depression, non-PTSD |
| PT-087 | Female with a view to preventing the formation of wrinkles | 50 | Anxious depression, non-PTSD |
| PT-077 | Female with a view to preventing the formation of wrinkles | 49 | With anxiety, depression, PTSD |
| PT-082 | Female with a view to preventing the formation of wrinkles | 25 | With anxiety, depression, PTSD |
| PT-095 | Female with a view to preventing the formation of wrinkles | 29 | With anxiety, depression, PTSD |
2) And collecting a blood sample: blood samples were collected by venipuncture in heparin-containing anticoagulation vacuum tubes, and 10ml blood samples were collected from each patient. The blood sample was centrifuged at 3000rpm for 5 minutes and separated into serum and plasma. All whole blood, serum and plasma were dispensed and stored in a-80 ℃ freezer for subsequent assays.
3) Identifying the protein content in the serum sample: the serum sample adopts a 4D-Label-free succinylation quantitative proteomics method to carry out protein content determination. The technology analyzes the proteolysis peptide section by liquid chromatography-mass spectrometry, does not need an expensive stable isotope Label as an internal Label, only needs to analyze mass spectrum data generated during large-scale protein identification, and compares the signal intensity of corresponding peptide sections in different samples, so that the corresponding protein can be relatively quantified. Taking out a serum sample from-80 ℃, weighing a proper amount of sample into a mortar precooled by liquid nitrogen, adding liquid nitrogen, and fully grinding the sample into powder. After adding lysis buffer to the powder, equal amounts of protein were taken from each sample for enzymatic hydrolysis. The peptide fragments obtained by enzymolysis are separated by a NanoElute ultra-performance liquid phase system, injected into a Capillary ion source for ionization and then analyzed by a timeTOF Pro mass spectrum. And (3) carrying out database search by adopting analysis software based on raw files obtained by mass spectrum detection, carrying out quality control on peptide fragments and protein levels based on search results, carrying out protein annotation, and then carrying out quantitative analysis on the protein.
4) And the result is as follows: comparing the protein content of patients with anxiety and depression symptoms and patients without anxiety and depression symptoms who have undergone brain trauma, a group of proteins differentially expressed in patients with anxiety and depression symptoms was identified, and the results are shown in table two:
table two: protein specific for patient with anxiety depression symptoms
Figure 1 shows that the protein levels of BCHE are significantly reduced in serum of patients with symptoms of anxious depression (p <0.05) compared to patients without symptoms of anxious depression. Figure 2 shows that the protein levels of CAT in serum were significantly reduced (p <0.05) in patients with symptoms of anxious depression compared to patients without symptoms of anxious depression. Figure 3 shows that the protein level of DBH in serum was significantly reduced (p <0.05) in patients with anxiety-depressive symptoms compared to patients without anxiety-depressive symptoms. Figure 4 shows that the protein levels of IGFBP2 are significantly reduced in the serum of patients with symptoms of anxious depression (p <0.05) compared to patients without symptoms of anxious depression. Figure 5 shows that NRP1 protein levels in serum were significantly reduced in patients with symptoms of anxious depression (p <0.05) compared to patients without symptoms of anxious depression.
5) And summarizing: 5 proteins were found which significantly distinguish patients with anxiety and depression symptoms after stress from patients without anxiety and depression symptoms. Including (1) butyrylcholinesterase BCHE (SwissProt P06276), according to the results of DIA mass spectrometry, BCHE was reduced by about 44% in serum samples from patients with anxiety depression symptoms compared to patients without anxiety depression symptoms. (2) The catalase CAT (SwissProt P04040), according to the results of DIA mass spectrometry, reduced CAT by about 47% in serum samples from patients with anxiety depression symptoms compared to patients without anxiety depression symptoms. (3) Dopamine-beta-hydroxylase DBH (SwissProt P09172), as a result of DIA mass spectrometry, reduces DBH by about 52% in serum samples from patients with anxiety depression symptoms compared to patients without anxiety depression symptoms. (4) Insulin-like growth factor binding protein 2IGFBP2(SwissProt P18065), as a result of DIA mass spectrometry, reduced IGFBP2 in serum samples from patients with anxiety-depressive symptoms by about 75% compared to patients without anxiety-depressive symptoms. (5) Neuropilin 1NRP1(SwissProt O14786), as a result of DIA mass spectrometry, reduced NRP1 in serum samples from patients with anxiety-depressive symptoms by about 23% compared to patients without anxiety-depressive symptoms.
4. Application of biomarker immunoassay kit for psychopsychological symptoms such as anxiety and depression after stress
1) And a subject: the use of the kit to recruit 16 healthy subjects and 15 outpatients who had experienced a traumatic event for the detection of the kit, the demographics of these subjects are as shown in table three:
table three: demographic data of the subject
2) And collecting a blood sample: blood samples were collected by venipuncture in heparin-containing anticoagulation vacuum tubes, and 10ml blood samples were collected from each patient. The blood sample was centrifuged at 3000rpm for 5 minutes and separated into serum and plasma. All whole blood, serum and plasma were dispensed and stored in a-80 ℃ freezer for subsequent assays.
3) And protein content of biomarker for psychosocial symptoms such as anxiety and depression after stress detection in serum sample: the serum sample adopts the kit of the invention, and the protein contents of butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2 and neuropilin1 are respectively detected by an ELISA method.
4) And the result is as follows: the results of the serum test for 31 subjects are shown in table four:
table four: ELISA detection result of biomarker of psychopsychological symptoms such as anxiety and depression after stress of subject
5) And data analysis: according to the results in the table four, the average value, the standard deviation and the 95% CI interval of the content of the biomarker protein of the psychosocial symptoms such as anxiety and depression after stress of healthy control subjects and subjects who have suffered from traumatic events are respectively calculated, and the results are shown in the table five:
table five: analysis data table of marker detection results of psychopsychological symptoms such as anxiety and depression after stress of subjects
6) And summarizing: the expression levels of the markers of psychophysiological symptoms such as anxiety and depression after stress in the serum of healthy control subjects and subjects who have suffered from traumatic events are respectively as follows: BCHE: 2748 ± 158.4ng/ml (healthy control) and 3064 ± 237.8ng/ml (wound group); CAT: 59.69 + -4.083 pg/ml (healthy control) and 67.24 + -3.718 pg/ml (wound group); DBH: 24.15 + -5.577 ng/ml (healthy control) and 25.29 + -7.149 ng/ml (wound group); IGFBP 2: 142.2. + -. 19.85ng/ml (healthy control) and 276.6. + -. 34.95ng/ml (wound group); NRP 1: 265.2 + -11.31 ng/ml (healthy control) and 239.2 + -17.66 ng/ml (wound group).
5. Determination of high risk threshold of biomarkers for psychophysiological symptoms such as anxiety and depression after stress
1) The reduction rate of expression levels of BCHE, CAT, DBH, IGFBP2 and NRP1 of a patient with anxiety and depression symptoms after stress, which is determined by a quantitative proteomics group, compared with a patient without anxiety and depression symptoms, and the expression level of the protein in the serum of a subject suffering from a traumatic event determined by the kit are combined to calculate the high risk cutoff threshold of the marker, and the calculation formula is as follows:
the Cutoff calculation formula is as follows: the mean expression level of the wound group determined by ELISA × (1-the rate of decrease in expression of patients with anxiety and depression symptoms determined by quantitative mass spectrometry)
The high risk threshold of the biomarker for each psychophysiological symptom such as anxiety and depression after stress is calculated according to the formula and the average expression of the trauma group in the fourth table and is respectively less than the following expression:
BCHE：3064×(1-44％)＝1716ng/ml；
CAT：67.24×(1-47％)＝35.64pg/ml；
DBH：25.29×(1-52％)＝12.14ng/ml；
IGFBP2：276.6×(1-75％)＝69.15ng/ml；
NRP1：239.2×(1-23％)＝184.2ng/ml。
2) and determining the risk of the detected stress patient according to the cutoff value, wherein the risk is considered to be high when the cutoff value is lower than the cutoff value, and the risk of the mental diseases such as anxiety, depression and PTSD is considered to be high when only one protein is detected to be high.
The invention obtains a group of biomarkers which can effectively predict the occurrence risk of psychopsychological symptoms such as anxiety and depression after stress by screening through a non-standard (Label-free) proteome quantitative technology and comparing the content of protein in blood samples of patients who have anxiety and depression after brain trauma and patients without anxiety and depression: BCHE, CAT, DBH, IGFBP2, and NRP 1. The invention prepares an immunoassay kit for detecting expression level in a blood sample according to the identified biomarkers of psychological symptoms such as anxiety and depression after stress and establishes a detection method. The blood sandwich enzyme-labeled immunoassay (sandwich ELISA) provided by the invention is based on the immune biochemical principle, and provides an antigen-antibody detection method with high sensitivity, high specificity and high stability. The prepared kit is repeatedly screened and verified by using the serum of healthy controls and patients who have suffered traumatic events, so that the biomarker detection kit for psychopsychological symptoms such as anxiety and depression after stress with high sensitivity, high specificity and high stability is obtained. And by combining the analysis mass spectrum quantitative data and the ELISA result, the biomarker concentration threshold value for predicting high occurrence risk of mental diseases such as anxiety, depression, PTSD and the like in the target population is given. The blood ELISA detection kit is quicker and simpler to operate; the accuracy and the precision of the detection result are greatly improved; the cost is low, the popularization is easy, and the method is suitable for the market. The ELISA detection method can be used as a large-scale screening tool for early screening of mental diseases after stress through optimization of various parameters and experimental processes.
In conclusion, the invention provides a group of biomarkers capable of predicting the occurrence of psychological symptoms such as anxiety and depression after stress and a detection kit and a detection method for detecting the biomarkers in a blood sample, and potential patients can use the kit to detect the concentrations of the proteins in the blood with high specificity, high sensitivity and high specificity after experiencing a stress event, and can provide basis for doctors to accurately predict the anxiety, depression, PTSD and other mental diseases of the stress patients according to the high risk threshold range provided by the invention, so that the treatment can be timely taken to prevent the occurrence of the diseases and relieve the pain and burden of the patients, and the immunodetection kit prepared from the biomarkers can quickly, simply and accurately detect the concentrations of the biomarkers in the blood, and is suitable for large-scale popularization and application.
In this specification, the invention has been described with reference to specific embodiments thereof. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention. The description is thus to be regarded as illustrative instead of limiting.
Claims (6)
1. An immunoassay kit for predicting the onset of psychosomatic symptoms after stress, said immunoassay kit comprising reagents for quantitatively detecting the expression level of a biomarker selected from the group consisting of: butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2, neuropilin1, an amino acid sequence having at least 80% homology with the amino acid sequence of butyrylcholinesterase, an amino acid sequence having at least 80% homology with the amino acid sequence of catalase, an amino acid sequence having at least 80% homology with the amino acid sequence of dopamine-beta-hydroxylase, an amino acid sequence having at least 80% homology with the amino acid sequence of insulin-like growth factor binding protein 2, and an amino acid sequence having at least 80% homology with the amino acid sequence of neuropilin 1.
2. The immunoassay kit of claim 1, further comprising a carrier, wherein the reagent is coated on the carrier.
3. The immunoassay kit of claim 1, wherein the reagent comprises a primary antibody to the biomarker.
4. The immunoassay kit of claim 3, wherein said reagents comprise a labeled secondary antibody to a primary antibody of said biomarker.
5. Use of a biomarker for the preparation of a reagent for the detection of the occurrence of a psychological symptom predictive of post-stress, wherein said reagent is a reagent for the quantitative determination of the level of expression of said biomarker, and said biomarker is selected from the group consisting of: butyrylcholinesterase, catalase, dopamine-beta-hydroxylase, insulin-like growth factor binding protein 2, neuropilin1, an amino acid sequence having at least 80% homology with the amino acid sequence of butyrylcholinesterase, an amino acid sequence having at least 80% homology with the amino acid sequence of catalase, an amino acid sequence having at least 80% homology with the amino acid sequence of dopamine-beta-hydroxylase, an amino acid sequence having at least 80% homology with the amino acid sequence of insulin-like growth factor binding protein 2, and an amino acid sequence having at least 80% homology with the amino acid sequence of neuropilin 1.
6. The use according to claim 5, wherein the psycho-psychological symptoms comprise one or more of post-stress anxiety, post-stress depression, post-traumatic stress disorder, post-stroke anxiety, post-stroke depression, post-brain trauma anxiety, or post-brain trauma depression.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111475342.5A CN114137214B (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
| CN202311409525.6A CN117451995A (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111475342.5A CN114137214B (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311409525.6A Division CN117451995A (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114137214A true CN114137214A (en) | 2022-03-04 |
| CN114137214B CN114137214B (en) | 2024-03-01 |
Family
ID=80383932
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111475342.5A Active CN114137214B (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
| CN202311409525.6A Pending CN117451995A (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311409525.6A Pending CN117451995A (en) | 2021-12-06 | 2021-12-06 | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114137214B (en) |
Citations (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| US20040014141A1 (en) * | 2002-04-18 | 2004-01-22 | Woolf Clifford J. | DRG11-responsive (dragon) gene family |
| CN1541107A (en) * | 2000-09-22 | 2004-10-27 | ��ʿ����ѧ | Growth factor complex |
| US20050084880A1 (en) * | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| WO2007106685A2 (en) * | 2006-03-10 | 2007-09-20 | Novartis Ag | Targets for depression and bipolar disorders |
| US20100100333A1 (en) * | 2008-10-15 | 2010-04-22 | Ridge Diagnostics, Inc. | Human biomarker hypermapping for depressive disorders |
| US20100233079A1 (en) * | 2008-12-04 | 2010-09-16 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| CN101903777A (en) * | 2007-12-19 | 2010-12-01 | 赛诺瓦神经学科技有限公司 | Be used to diagnose and monitor the method and the biomarker of mental illness |
| US20110044980A1 (en) * | 2009-07-29 | 2011-02-24 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20110294693A1 (en) * | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| CN103492590A (en) * | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers |
| US20140200151A1 (en) * | 2010-12-20 | 2014-07-17 | Cambridge Enterprise Limited | Biomarkers |
| US20140200150A1 (en) * | 2010-12-20 | 2014-07-17 | Cambridge Enterprise Limited | Biomarkers |
| US20150119269A1 (en) * | 2012-04-24 | 2015-04-30 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury |
| WO2015082927A1 (en) * | 2013-12-05 | 2015-06-11 | Cambridge Enterprise Limited | Novel biomarker panel for major depressive disease |
| US20150259740A1 (en) * | 2011-09-14 | 2015-09-17 | Harvey Pollard | Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder |
| US20150301058A1 (en) * | 2012-11-26 | 2015-10-22 | Caris Science, Inc. | Biomarker compositions and methods |
| CN106062563A (en) * | 2014-01-28 | 2016-10-26 | 普雷德姆泰克有限公司 | Biomarker and methods for early diagnosis of alzheimer's disease |
| US20160319361A1 (en) * | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
| US20170016921A1 (en) * | 2014-03-10 | 2017-01-19 | Cambridge Enterprise Limited | Novel biomarkers |
| US20170258843A1 (en) * | 2016-03-14 | 2017-09-14 | AngioStem, Inc. | Stem cell mediated neuroregeneration and neuroprotection |
| EP3232198A1 (en) * | 2014-12-12 | 2017-10-18 | Seoul National University R&DB Foundation | Biomarker for diagnosis of hepatoma and use thereof |
| US20170356903A1 (en) * | 2014-11-21 | 2017-12-14 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| CN107921094A (en) * | 2015-06-04 | 2018-04-17 | 圣拉斐尔医院有限公司 | IGFBP3 and application thereof |
| US20180161377A1 (en) * | 2016-12-09 | 2018-06-14 | Neoneuron Llc | Method of treating neurological disorders with stem cell therapy |
| JP2018132526A (en) * | 2017-02-16 | 2018-08-23 | 国立大学法人千葉大学 | Markers, method for inspection, and inspection kit for major depressive disorder and bipolar disorder, and method for screening therapeutic medicines for major depressive disorder and bipolar disorder |
| CN108441551A (en) * | 2017-04-11 | 2018-08-24 | 刘小翠 | A kind of biomarker and its application process of phrenoblabia |
| US20200397828A1 (en) * | 2019-04-29 | 2020-12-24 | The Broad Institute, Inc. | Atlas of choroid plexus cell types and therapeutic and diagnostic uses thereof |
| US20210009639A1 (en) * | 2019-07-12 | 2021-01-14 | Northwestern University | Insulin like growth factor binding protein bioactive peptide fragments |
| CN112957453A (en) * | 2021-03-04 | 2021-06-15 | 上海市精神卫生中心（上海市心理咨询培训中心） | Application of insulin-like growth factor binding protein 2 in preparation of medicine for treating mental disorder caused by brain trauma |
-
2021
- 2021-12-06 CN CN202111475342.5A patent/CN114137214B/en active Active
- 2021-12-06 CN CN202311409525.6A patent/CN117451995A/en active Pending
Patent Citations (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
| CN1541107A (en) * | 2000-09-22 | 2004-10-27 | ��ʿ����ѧ | Growth factor complex |
| US20040014141A1 (en) * | 2002-04-18 | 2004-01-22 | Woolf Clifford J. | DRG11-responsive (dragon) gene family |
| US20050084880A1 (en) * | 2003-07-11 | 2005-04-21 | Ronald Duman | Systems and methods for diagnosing & treating psychological and behavioral conditions |
| WO2007106685A2 (en) * | 2006-03-10 | 2007-09-20 | Novartis Ag | Targets for depression and bipolar disorders |
| CN101903777A (en) * | 2007-12-19 | 2010-12-01 | 赛诺瓦神经学科技有限公司 | Be used to diagnose and monitor the method and the biomarker of mental illness |
| US20100100333A1 (en) * | 2008-10-15 | 2010-04-22 | Ridge Diagnostics, Inc. | Human biomarker hypermapping for depressive disorders |
| US20110294693A1 (en) * | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| US20100233079A1 (en) * | 2008-12-04 | 2010-09-16 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20110044980A1 (en) * | 2009-07-29 | 2011-02-24 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| US20140200151A1 (en) * | 2010-12-20 | 2014-07-17 | Cambridge Enterprise Limited | Biomarkers |
| US20140200150A1 (en) * | 2010-12-20 | 2014-07-17 | Cambridge Enterprise Limited | Biomarkers |
| CN103492590A (en) * | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | Circulating biomarkers |
| US20150259740A1 (en) * | 2011-09-14 | 2015-09-17 | Harvey Pollard | Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder |
| US20150119269A1 (en) * | 2012-04-24 | 2015-04-30 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury |
| US20150301058A1 (en) * | 2012-11-26 | 2015-10-22 | Caris Science, Inc. | Biomarker compositions and methods |
| US20160319361A1 (en) * | 2013-08-28 | 2016-11-03 | Caris Life Sciences Switzerland Holdings Gmbh | Oligonucleotide probes and uses thereof |
| WO2015082927A1 (en) * | 2013-12-05 | 2015-06-11 | Cambridge Enterprise Limited | Novel biomarker panel for major depressive disease |
| CN106062563A (en) * | 2014-01-28 | 2016-10-26 | 普雷德姆泰克有限公司 | Biomarker and methods for early diagnosis of alzheimer's disease |
| US20170016921A1 (en) * | 2014-03-10 | 2017-01-19 | Cambridge Enterprise Limited | Novel biomarkers |
| US20170356903A1 (en) * | 2014-11-21 | 2017-12-14 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| EP3232198A1 (en) * | 2014-12-12 | 2017-10-18 | Seoul National University R&DB Foundation | Biomarker for diagnosis of hepatoma and use thereof |
| CN107921094A (en) * | 2015-06-04 | 2018-04-17 | 圣拉斐尔医院有限公司 | IGFBP3 and application thereof |
| US20170258843A1 (en) * | 2016-03-14 | 2017-09-14 | AngioStem, Inc. | Stem cell mediated neuroregeneration and neuroprotection |
| US20180161377A1 (en) * | 2016-12-09 | 2018-06-14 | Neoneuron Llc | Method of treating neurological disorders with stem cell therapy |
| JP2018132526A (en) * | 2017-02-16 | 2018-08-23 | 国立大学法人千葉大学 | Markers, method for inspection, and inspection kit for major depressive disorder and bipolar disorder, and method for screening therapeutic medicines for major depressive disorder and bipolar disorder |
| CN108441551A (en) * | 2017-04-11 | 2018-08-24 | 刘小翠 | A kind of biomarker and its application process of phrenoblabia |
| US20200397828A1 (en) * | 2019-04-29 | 2020-12-24 | The Broad Institute, Inc. | Atlas of choroid plexus cell types and therapeutic and diagnostic uses thereof |
| US20210009639A1 (en) * | 2019-07-12 | 2021-01-14 | Northwestern University | Insulin like growth factor binding protein bioactive peptide fragments |
| CN112957453A (en) * | 2021-03-04 | 2021-06-15 | 上海市精神卫生中心（上海市心理咨询培训中心） | Application of insulin-like growth factor binding protein 2 in preparation of medicine for treating mental disorder caused by brain trauma |
| CN112972652A (en) * | 2021-03-04 | 2021-06-18 | 上海市精神卫生中心（上海市心理咨询培训中心） | Application of insulin-like growth factor binding protein 2 in preparation of medicine for resisting mental disorder caused by early stress |
| CN113144173A (en) * | 2021-03-04 | 2021-07-23 | 上海市精神卫生中心（上海市心理咨询培训中心） | Application of insulin-like growth factor binding protein 2 in preparation of medicine for treating mental disorder caused by stress in adult period |
Non-Patent Citations (5)
| Title |
|---|
| BURGDORF J, ET AL.: "IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity", THE INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 1 June 2017 (2017-06-01) * |
| D O MINCHENKO ET AL.: "Expression of insulin-like growth factor binding protein genes and its hypoxic regulation in U87 glioma cells depends on ERN1 mediated signaling pathway of endoplasmic reticulum stress.", ENDOCR REGUL., vol. 49, 31 December 2015 (2015-12-31) * |
| JYOTI, YADAV ET AL.: "Sialic acid associated with oxidative stress and total antioxidant capacity (TAC) expression level as a predictive indicator in moderate to severe Alzheimer\'s disease.", EXP GERONTOL., vol. 141, 31 December 2020 (2020-12-31) * |
| 刘世钰 等: "基于组学技术的抑郁症相关生物标志物研究进展", 药学实践杂志, no. 03, 25 May 2018 (2018-05-25) * |
| 樊键 等: "精神创伤后应激障碍的神经递质水平相关性", 中国健康心理学杂志, no. 08, 15 August 2013 (2013-08-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117451995A (en) | 2024-01-26 |
| CN114137214B (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI708058B (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
| US20220026448A1 (en) | Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury | |
| US8697370B2 (en) | Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof | |
| US9200322B2 (en) | Biomarkers for acute ischemic stroke | |
| US20120178637A1 (en) | Biomarkers and methods for detecting alzheimer's disease | |
| Galli et al. | Increased serum levels of mesencephalic astrocyte-derived neurotrophic factor in subjects with Parkinson’s disease | |
| US9977036B2 (en) | Diagnostic markers for multiple sclerosis | |
| CN110702930B (en) | Application of 24-hydroxycholesterol in preparation of related products for diagnosis and treatment of depression | |
| CN114410773A (en) | Marker combination for predicting or diagnosing depression recurrence and application thereof | |
| US20090263822A1 (en) | In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases | |
| WO2023143327A1 (en) | Use of hypoxia-inducible factor 1 alpha as marker in depression recurrence diagnosis | |
| CN110988351B (en) | Application of vascular cell adhesion molecule in preparing related products for diagnosis and treatment of depression | |
| WO2016004375A2 (en) | Methods and materials for treating pain and depression | |
| CN114137214B (en) | Immunodetection kit for predicting occurrence of mental symptoms after stress and application thereof | |
| Lertpanprom et al. | High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma | |
| US20230258660A1 (en) | A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions | |
| JP2023537749A (en) | IGFBP7 for assessment of asymptomatic stroke and cognitive decline | |
| CN116547536A (en) | GDF-15 for predicting disease severity in patients with COVID-19 | |
| RU2216741C1 (en) | Diagnostic kit for detecting schizophrenia | |
| JPWO2019099732A5 (en) | ||
| JP2020519895A (en) | Diagnostic biomarkers for detecting, subtyping and/or assessing progression of multiple sclerosis | |
| WO2014184534A1 (en) | Marker for response to antidepressant therapy | |
| US20230190967A1 (en) | Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent | |
| CN110988369B (en) | Application of 27-hydroxycholesterol in preparation of antidepressant drug efficacy-related products | |
| EP3730942A1 (en) | Diagnosis markers for atrial fibrillation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |